2018 Objectives and Outlook

2018 Outlook

MDKK2018
Guidance
2017
Actual Result
Revenue2,700 - 3,1002,365
Operating expenses(1,400) – (1,600)(1,021)
Operating income1,300 – 1,5001,344

2018 Goals

Priority
Maximize Daratumumab Progress
Targeted Milestone
  • FDA and EMA decision on Phase III ALCYONE multiple myeloma (MM) submsission
  • Start new Phase III MM study
  • Report early clinical data in solid tumors
  • Phase III MAIA MM efficacy analysis in frontline
  • Phase III CASSIOPEIA MM efficacy analysis in frontline
Optimize Ofatumumab Value
  • Complete recruitment Phase III subcutaneous ofatumumab relapsing MS sutides
Maximize Tisotumab Vedotin Progress
  • Start two Phase II studies cervical cancer (recurrent / metastatic & combination study in frontline)
  • Start Phase II study in additional solid tumor indications
Strengthen Differentiated Product Pipeline And Technology Partnership Portfolio
  • Start HuMax-AXL-ADC expansion phase in ongoing Phase I/II study
  • Progress HexaBody-DR5/DR5 Phase I/II study
  • Progress DuoBody-CD3xCD20 Phase I/II study
  • Accelerate proprietary Immuno-Oncology DuoBody programs towards clinic
  • Enter new technology or product collaborations
Disciplined Financial Management And Building A Commercial Footprint
  • Execute controlled company growth with selective investments in product & technology pipeline
  • Continue investing in building commercialization and launch capabilities